focus -WSS

focus

author：focus 2025-10-02 18:06:06 - browse：9

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： STAT Virtual Event: Putting AI to the Test

WSS

Drug for rare kidney disease narrowly misses mark in clinical trial

Life science postdocs should get big pay hike, NIH panel says

Male doctors called my cancer incurable. A female doctor showed it wasn't

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Medicare Advantage overpayments discussion gets experts fired up

In shift, Texas to cover initial consult for Afghan baby's gene therapy

focus

focus

Wikipedia

Drug repurposing or repositioning? The language matters

Lasker Awards 2023: Winners in biomedical research

BioMarin wins approval for gene therapy to treat hemophilia A

CommonSpirit Health keeps growing, even as it loses money

DIEP, the 'gold standard' of breast reconstruction, is under threat

Ukraine and a new approach to mental health in war

Bright Health sells Medicare Advantage business to Molina

Medical student insurance fails on mental health care coverage

The high cost of giving birth even with insurance

Hearing on Medicare drug price negotiation gets unusually heated

focus

Emergency workers more likely to restrain Black patients: study

Emergency workers more likely to restrain Black patients: study

Does Paxlovid work in people vaccinated against Covid

CommonSpirit Health keeps growing, even as it loses money

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Hearing on Medicare drug price negotiation gets unusually heated

hotspot

focus

knowledge

hotspot